ResearcherUniversity of Silesia in KatowiceActive in the last 2 years

Katarzyna Malarz

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4283-3126; OpenAlex author ID A5085177357. Sources: OpenAlex.

Their work

Papers: 2 (first author 1, last author 0)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2020: 1 paper · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 1 paper

Papers 2

Aminofullerenes as targeted inhibitors of EGFR: from pancreatic cancer inhibitors to Drosophila m. Toxicology. Co-author DOI 10.1080/17435889.2025.2461985 ↗
Glycofullerenes as non-receptor tyrosine kinase inhibitors- towards better nanotherapeutics for pancreatic cancer treatment. First author DOI 10.1038/s41598-019-57155-7 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Maciej Serda · 2 shared papers, 2020–2025 · strength 0.35
- Paper Aminofullerenes as targeted inhibitors of EGFR: from pancreatic cancer inhibitors to Drosophila m. Toxicology. DOI 10.1080/17435889.2025.2461985 ↗
- Paper Glycofullerenes as non-receptor tyrosine kinase inhibitors- towards better nanotherapeutics for pancreatic cancer treat… DOI 10.1038/s41598-019-57155-7 ↗
Tao Sun · 1 shared paper, 2025 · strength 0.22
- Paper Aminofullerenes as targeted inhibitors of EGFR: from pancreatic cancer inhibitors to Drosophila m. Toxicology. DOI 10.1080/17435889.2025.2461985 ↗
Steven A. Curley · 1 shared paper, 2020 · strength 0.13
- Paper Glycofullerenes as non-receptor tyrosine kinase inhibitors- towards better nanotherapeutics for pancreatic cancer treat… DOI 10.1038/s41598-019-57155-7 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.